TY - JOUR
T1 - Radioimmunotherapy for the treatment of non-Hodgkin lymphoma
T2 - Current status and future applications
AU - Ahmed, Sairah
AU - Winter, Jane N.
AU - Gordon, Leo I.
AU - Evens, Andrew M.
PY - 2010/7
Y1 - 2010/7
N2 - Radioimmunotherapy (RIT) has proved to be a safe and effective treatment for patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) including rituximab-refractory follicular lymphoma. Further, FDA approval was recently granted for use in newly diagnosed follicular lymphoma as consolidative therapy immediately following induction chemotherapy. We detail herein the scope of clinical studies performed in relapsed/refractory and newly diagnosed indolent lymphoma and summarize the associated safety data. In addition, we discuss new applications of RIT that have been investigated in a variety of clinical scenarios (e.g. single-agent and sequential therapy in aggressive NHLs and as a component of stem cell transplant conditioning). The wide array of RIT-based studies have yielded encouraging data, although randomized controlled trials will be needed to prove superiority over conventional therapy. Novel therapeutic RIT-based strategies that continue to be explored include radiation-enhancing agents combined with RIT, pre-targeting, RIT fractionation, as well as the integration of new humanized antibodies. The field of RIT continues to evolve scientifically and grow clinically. A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL.
AB - Radioimmunotherapy (RIT) has proved to be a safe and effective treatment for patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) including rituximab-refractory follicular lymphoma. Further, FDA approval was recently granted for use in newly diagnosed follicular lymphoma as consolidative therapy immediately following induction chemotherapy. We detail herein the scope of clinical studies performed in relapsed/refractory and newly diagnosed indolent lymphoma and summarize the associated safety data. In addition, we discuss new applications of RIT that have been investigated in a variety of clinical scenarios (e.g. single-agent and sequential therapy in aggressive NHLs and as a component of stem cell transplant conditioning). The wide array of RIT-based studies have yielded encouraging data, although randomized controlled trials will be needed to prove superiority over conventional therapy. Novel therapeutic RIT-based strategies that continue to be explored include radiation-enhancing agents combined with RIT, pre-targeting, RIT fractionation, as well as the integration of new humanized antibodies. The field of RIT continues to evolve scientifically and grow clinically. A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL.
KW - Non-Hodgkin lymphoma
KW - radioimmunotherapy
KW - stem cell transplant
UR - http://www.scopus.com/inward/record.url?scp=77954102491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954102491&partnerID=8YFLogxK
U2 - 10.3109/10428191003793366
DO - 10.3109/10428191003793366
M3 - Review article
C2 - 20470217
AN - SCOPUS:77954102491
SN - 1042-8194
VL - 51
SP - 1163
EP - 1177
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -